AU2017260873B2 - Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases - Google Patents
Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases Download PDFInfo
- Publication number
- AU2017260873B2 AU2017260873B2 AU2017260873A AU2017260873A AU2017260873B2 AU 2017260873 B2 AU2017260873 B2 AU 2017260873B2 AU 2017260873 A AU2017260873 A AU 2017260873A AU 2017260873 A AU2017260873 A AU 2017260873A AU 2017260873 B2 AU2017260873 B2 AU 2017260873B2
- Authority
- AU
- Australia
- Prior art keywords
- steroid
- cbd
- dose
- subject
- functional derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/143,694 US9889100B2 (en) | 2013-05-02 | 2016-05-02 | Cannabidiol for treatment of severe and refractory graft-versus-host disease |
| US15/143,694 | 2016-05-02 | ||
| PCT/IL2017/050483 WO2017191630A1 (fr) | 2016-05-02 | 2017-05-01 | Cannabidiol utilisé pour réduire une dose de stéroïde et pour traiter des maladies inflammatoires et auto-immunes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017260873A1 AU2017260873A1 (en) | 2018-11-29 |
| AU2017260873B2 true AU2017260873B2 (en) | 2023-03-02 |
Family
ID=60203614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017260873A Active AU2017260873B2 (en) | 2016-05-02 | 2017-05-01 | Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3452046A4 (fr) |
| KR (1) | KR102537990B1 (fr) |
| CN (2) | CN109414443A (fr) |
| AU (1) | AU2017260873B2 (fr) |
| CA (1) | CA3022900A1 (fr) |
| IL (1) | IL262713B2 (fr) |
| WO (1) | WO2017191630A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220265574A1 (en) * | 2013-05-02 | 2022-08-25 | Stero Biotechs Ltd. | Methods of using cannabidiol and a steroid |
| CN119632928A (zh) | 2019-10-03 | 2025-03-18 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 数个脂质体大麻素及其用途 |
| EP4072558A4 (fr) * | 2019-12-13 | 2023-12-20 | Buzzelet Development And Technologies Ltd | Compositions et procédés pour le traitement de l'inflammation avec des stéroïdes et un modulateur |
| AU2021223191A1 (en) * | 2020-02-19 | 2022-10-13 | MERCHANT, Shreema | Compositions and therapeutic uses of cannabidiol |
| IL301161A (en) * | 2020-09-06 | 2023-05-01 | Medicane Res & Development Ltd | The composition including cannabinoids and/or terpenes and methods for using it |
| CN113398104B (zh) * | 2021-07-14 | 2022-04-08 | 北京森宏健康科技有限公司 | 大麻二酚在治疗胆红素脑病中的用途 |
| WO2023058016A1 (fr) * | 2021-10-04 | 2023-04-13 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Institute) | Médicaments anti-inflammatoires non stéroïdiens et cannabinoïdes et leurs utilisations |
| WO2025107042A1 (fr) * | 2023-11-22 | 2025-05-30 | Algorae Pharmaceuticals Ltd | Compositions et méthodes pour le traitement ou la prévention de maladies ou de troubles cardiovasculaires |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274635B1 (en) * | 1999-03-22 | 2001-08-14 | Immugen Pharmaceuticals Inc. | Alkylated resorcinol derivatives for the treatment of immune diseases |
| US20090005461A1 (en) * | 2007-06-18 | 2009-01-01 | University Of South Carolina | Use of Cannabidiol in the Treatment of Hepatitis |
| US20110195096A1 (en) * | 2008-07-31 | 2011-08-11 | Dekel Pharmaceuticals Ltd. | Compositions and methods for treating inflammatory disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070060638A1 (en) * | 2005-08-26 | 2007-03-15 | Olmstead Mary C | Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist |
| US9889100B2 (en) * | 2013-05-02 | 2018-02-13 | Mor Research Applications Ltd. | Cannabidiol for treatment of severe and refractory graft-versus-host disease |
-
2017
- 2017-05-01 AU AU2017260873A patent/AU2017260873B2/en active Active
- 2017-05-01 WO PCT/IL2017/050483 patent/WO2017191630A1/fr not_active Ceased
- 2017-05-01 CA CA3022900A patent/CA3022900A1/fr active Pending
- 2017-05-01 EP EP17792603.7A patent/EP3452046A4/fr active Pending
- 2017-05-01 CN CN201780040985.2A patent/CN109414443A/zh active Pending
- 2017-05-01 CN CN202311190299.7A patent/CN117017998A/zh active Pending
- 2017-05-01 IL IL262713A patent/IL262713B2/en unknown
- 2017-05-01 KR KR1020187034907A patent/KR102537990B1/ko active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274635B1 (en) * | 1999-03-22 | 2001-08-14 | Immugen Pharmaceuticals Inc. | Alkylated resorcinol derivatives for the treatment of immune diseases |
| US20090005461A1 (en) * | 2007-06-18 | 2009-01-01 | University Of South Carolina | Use of Cannabidiol in the Treatment of Hepatitis |
| US20110195096A1 (en) * | 2008-07-31 | 2011-08-11 | Dekel Pharmaceuticals Ltd. | Compositions and methods for treating inflammatory disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3452046A4 (fr) | 2020-02-19 |
| IL262713B1 (en) | 2024-03-01 |
| CN109414443A (zh) | 2019-03-01 |
| KR20190016952A (ko) | 2019-02-19 |
| IL262713A (en) | 2018-12-31 |
| IL262713B2 (en) | 2024-07-01 |
| WO2017191630A1 (fr) | 2017-11-09 |
| AU2017260873A1 (en) | 2018-11-29 |
| CA3022900A1 (fr) | 2017-11-09 |
| CN117017998A (zh) | 2023-11-10 |
| EP3452046A1 (fr) | 2019-03-13 |
| KR102537990B1 (ko) | 2023-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017260873B2 (en) | Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases | |
| JP2022064988A (ja) | カンナビジオールによる脆弱x症候群の処置 | |
| CN109152774A (zh) | 眼部炎性病症和疾病的组合治疗 | |
| US11357740B2 (en) | Cannabidiol for enhancing the therapeutic effect of a steroid | |
| AU2014249534B2 (en) | Use of levocetirizine and montelukast in the treatment of vasculitis | |
| EP2723330B1 (fr) | Agent de polythérapie contenant des vasoconstricteurs | |
| AU2014249530B2 (en) | Use of levocetirizine and montelukast in the treatment of anaphylaxis | |
| CN113274342B (zh) | 一种秋水仙碱外用组合物 | |
| US10660865B2 (en) | Cannabidiol for the prevention and treatment of graft-versus-host disease | |
| JPWO2006041121A1 (ja) | 慢性皮膚疾患の治療および/または予防剤 | |
| EP2808025B1 (fr) | Composition pharmaceutique et produit cosmétique quasi-médicamenteux utilisant celle-ci | |
| WO2020106191A1 (fr) | Production de glutarimide pour vaincre la résistance aux stéroïdes | |
| CN114515293A (zh) | 一种毛蕊花糖苷在制备治疗雄激素性脱发药物中的应用 | |
| Ponticelli et al. | The pharmacology of old and new agents for specific therapy of primary glomerular diseases | |
| US20250099472A1 (en) | Ruxolitinib for the treatment of prurigo nodularis | |
| CN110891580A (zh) | 使用三氧化二砷治疗多发性硬化症的方法 | |
| US20140378426A1 (en) | Methods and compositions for enhancing visual function | |
| WO2025018279A1 (fr) | Agent thérapeutique contre une maladie du greffon contre l'hôte humain et combinaison associée | |
| US6277834B1 (en) | Agents for relieving side effects of adrenal cortex hormone | |
| WO2025096373A1 (fr) | Ruxolitinib destiné à être utilisé dans le traitement du prurigo nodulaire | |
| US20220265574A1 (en) | Methods of using cannabidiol and a steroid | |
| EA043839B1 (ru) | Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма | |
| MX2014012904A (es) | Carboxamidas y sus sales farmaceuticamente aceptables para usarse en el tratamiento de dermatosis sensibles a esteroides. | |
| KR20010032771A (ko) | 크로모글릭산 화합물의 의약 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |